Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.09
-0.47 (-4.45%)
Oct 30, 2026, 11:45 AM EDT - Market open
Kura Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 77.23 | 67.48 | 53.88 | - | - | - | |
Revenue Growth | -7.27% | 25.24% | - | - | - | - |
Cost of Revenue | 260.03 | 251.13 | 169.97 | 115.24 | 92.81 | - |
Gross Profit | -182.81 | -183.65 | -116.08 | -115.24 | -92.81 | - |
Selling, General & Admin | 135.28 | 119.98 | 77.11 | 50.57 | 47.05 | 46.54 |
Research & Development | - | - | - | - | - | 84.72 |
Operating Expenses | 135.28 | 119.98 | 77.11 | 50.57 | 47.05 | 131.26 |
Operating Income | -318.09 | -303.63 | -193.2 | -165.8 | -139.87 | -131.26 |
Interest Expense | -1.42 | -1.51 | -1.62 | -1.55 | -0.23 | -0.41 |
Interest & Investment Income | 14.33 | 18.29 | 9.71 | 5.3 | 5.86 | 5.6 |
EBT Excluding Unusual Items | -305.18 | -286.86 | -185.11 | -162.05 | -134.23 | -126.08 |
Gain (Loss) on Sale of Investments | 8.49 | 8.49 | 13.14 | 9.42 | -1.61 | -4.39 |
Pretax Income | -296.69 | -278.37 | -171.97 | -152.63 | -135.84 | -130.47 |
Income Tax Expense | 0.08 | 0.3 | 2.02 | - | - | - |
Net Income | -296.78 | -278.67 | -173.98 | -152.63 | -135.84 | -130.47 |
Net Income to Common | -296.78 | -278.67 | -173.98 | -152.63 | -135.84 | -130.47 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 88 | 88 | 86 | 73 | 67 | 66 |
Shares Outstanding (Diluted) | 88 | 88 | 86 | 73 | 67 | 66 |
Shares Change | 1.16% | 1.76% | 17.66% | 9.31% | 0.96% | 25.01% |
EPS (Basic) | -3.36 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 |
EPS (Diluted) | -3.36 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -117.43 | -70.7 | 133.85 | -124.99 | -110.69 | -105.7 |
Free Cash Flow Per Share | -1.33 | -0.81 | 1.55 | -1.71 | -1.65 | -1.59 |
Gross Margin | -236.72% | -272.14% | -215.44% | - | - | - |
Operating Margin | -411.90% | -449.94% | -358.54% | - | - | - |
Profit Margin | -384.30% | -412.95% | -322.89% | - | - | - |
Free Cash Flow Margin | -152.06% | -104.76% | 248.40% | - | - | - |
EBITDA | -316.8 | -302.6 | -192.35 | -164.96 | -139.11 | -130.7 |
D&A For EBITDA | 1.29 | 1.03 | 0.85 | 0.85 | 0.76 | 0.56 |
EBIT | -318.09 | -303.63 | -193.2 | -165.8 | -139.87 | -131.26 |
Revenue as Reported | 77.23 | 67.48 | 53.88 | - | - | - |
Advertising Expenses | - | 2.8 | - | - | - | - |